ID   SK-N-BE(2)-C
AC   CVCL_0529
SY   SK-N-BE(2)C; SK-N-BE-2c; SK-N-BE2(c); SK-N-BE(2C); SK-N-BE(2c); SK-N-BE2C; SK_N_BE2C; SKNBE2C; SKNBE(2c); BE(2)-C; BE(2)C; Be(2)C; BE2-C; BE2_C; Be2-C; BE2C; Be2C
DR   BTO; BTO:0004782
DR   CLO; CLO_0001915
DR   CLO; CLO_0009053
DR   EFO; EFO_0005725
DR   MCCL; MCC:0000428
DR   CLDB; cl413
DR   CLDB; cl4334
DR   ArrayExpress; E-MTAB-38
DR   ATCC; CRL-2268
DR   BioSample; SAMN03471855
DR   Cell_Model_Passport; SIDM01232
DR   Cosmic; 688061
DR   Cosmic; 922659
DR   Cosmic; 1162003
DR   Cosmic; 1167421
DR   Cosmic; 1526648
DR   ECACC; 95011817
DR   ENCODE; ENCBS271SFD
DR   ENCODE; ENCBS403ENC
DR   ENCODE; ENCBS427ENC
DR   ENCODE; ENCBS982TUR
DR   GEO; GSM651567
DR   GEO; GSM651568
DR   GEO; GSM945241
DR   GEO; GSM945283
DR   GEO; GSM923434
DR   GEO; GSM1022648
DR   GEO; GSM1022650
DR   GEO; GSM1022653
DR   GEO; GSM2371256
DR   GEO; GSM2394383
DR   GEO; GSM3145690
DR   GEO; GSM4104593
DR   GEO; GSM4104594
DR   GEO; GSM4105343
DR   GEO; GSM4105344
DR   GEO; GSM4105345
DR   GEO; GSM4105346
DR   GEO; GSM4105347
DR   IARC_TP53; 15544
DR   ICLC; HTL96018
DR   IGRhCellID; BE2C
DR   LINCS_LDP; LCL-1963
DR   NCBI_Iran; C577
DR   PRIDE; PXD003596
DR   Progenetix; CVCL_0529
DR   Wikidata; Q54954443
RX   PubMed=1985865;
RX   PubMed=2535691;
RX   PubMed=6582512;
RX   PubMed=8665486;
RX   PubMed=10630978;
RX   PubMed=11196202;
RX   PubMed=15150552;
RX   PubMed=15390183;
RX   PubMed=15720811;
RX   PubMed=15892104;
RX   PubMed=18724359;
RX   PubMed=19147553;
RX   PubMed=20215515;
RX   PubMed=23202128;
RX   PubMed=23325432;
RX   PubMed=24466371;
RX   PubMed=26342562;
RX   PubMed=28350380;
RX   PubMed=33525507;
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/BE2-C_Myers_protocol.pdf
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/b/cell-lines-detail-162.html
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/sk-n-be-2-c-human-neuroblastoma-cell-line
CC   Part of: ENCODE project common cell types; tier 3.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-532.
CC   Population: Caucasian.
CC   Characteristics: Intermediate type (I-type) (PubMed=15720811).
CC   Characteristics: MYCN-amplified NBL cell line.
CC   Doubling time: 18 hours (ATCC).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=11196202).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (PubMed=11196202).
CC   Omics: Array-based CGH.
CC   Omics: ATAC-seq.
CC   Omics: CTCF ChIP-seq epigenome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K27me3 ChIP-seq epigenome analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Single cell RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from metastatic site: Bone marrow.
ST   Source(s): ATCC; ECACC
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 9,11
ST   D5S818: 12
ST   D7S820: 9,10
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0528 ! SK-N-BE(2)
SX   Male
AG   2Y2M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-06-22; Version: 33
//
RX   PubMed=1985865; DOI=10.1002/ijc.2910470119;
RA   Lashford L.S., Hancock J.P., Kemshead J.T.;
RT   "Meta-iodobenzylguanidine (mIBG) uptake and storage in the human
RT   neuroblastoma cell line SK-N-BE(2C).";
RL   Int. J. Cancer 47:105-109(1991).
//
RX   PubMed=2535691;
RA   Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.;
RT   "Phenotypic diversification in human neuroblastoma cells: expression
RT   of distinct neural crest lineages.";
RL   Cancer Res. 49:219-225(1989).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=8665486; DOI=10.1016/0304-3835(96)04250-4;
RA   Diccianni M.B., Chau L.S., Batova A., Vu T.Q., Yu A.L.-T.;
RT   "The p16 and p18 tumor suppressor genes in neuroblastoma: implications
RT   for drug resistance.";
RL   Cancer Lett. 104:183-192(1996).
//
RX   PubMed=10630978; DOI=10.1667/0033-7587(2000)153[0062:FORIMI]2.0.CO;2;
RA   Akudugu J.M., Slabbert J.P., Serafin A., Bohm L.;
RT   "Frequency of radiation-induced micronuclei in neuronal cells does not
RT   correlate with clonogenic survival.";
RL   Radiat. Res. 153:62-67(2000).
//
RX   PubMed=11196202;
RA   Tweddle D.A., Malcolm A.J., Bown N., Pearson A.D., Lunec J.;
RT   "Evidence for the development of p53 mutations after cytotoxic therapy
RT   in a neuroblastoma cell line.";
RL   Cancer Res. 61:8-13(2001).
//
RX   PubMed=15150552; DOI=10.1038/sj.bjc.6601842;
RA   Airoldi I., Meazza R., Croce M., Di Carlo E., Piazza T., Cocco C.,
RA   D'Antuono T., Pistoia V., Ferrini S., Corrias M.V.;
RT   "Low-dose interferon-gamma-producing human neuroblastoma cells show
RT   reduced proliferation and delayed tumorigenicity.";
RL   Br. J. Cancer 90:2210-2218(2004).
//
RX   PubMed=15390183; DOI=10.1002/gcc.20096;
RA   Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.;
RT   "Expression profiles and clinical relationships of ID2, CDKN1B, and
RT   CDKN2A in primary neuroblastoma.";
RL   Genes Chromosomes Cancer 41:297-308(2004).
//
RX   PubMed=15720811; DOI=10.1593/neo.04310;
RA   Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F.,
RA   Biedler J.L., Cheung N.-K.V., Ross R.A.;
RT   "Characteristics of stem cells from human neuroblastoma cell lines and
RT   in tumors.";
RL   Neoplasia 6:838-845(2004).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=18724359; DOI=10.1038/nature07261;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
//
RX   PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856;
RA   Michaelis M., Rothweiler F., Klassert D., von Deimling A., Weber K.,
RA   Fehse B., Kammerer B., Doerr H.-W., Cinatl J. Jr.;
RT   "Reversal of P-glycoprotein-mediated multidrug resistance by the
RT   murine double minute 2 antagonist nutlin-3.";
RL   Cancer Res. 69:416-421(2009).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=23202128; DOI=10.1038/ng.2493;
RA   Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y.,
RA   Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.;
RT   "Integrated genomic analyses identify ARID1A and ARID1B alterations in
RT   the childhood cancer neuroblastoma.";
RL   Nat. Genet. 45:12-17(2013).
//
RX   PubMed=23325432; DOI=10.1101/gr.147942.112;
RA   Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E.,
RA   Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A.,
RA   Crawford G.E., Absher D.M., Wold B.J., Myers R.M.;
RT   "Dynamic DNA methylation across diverse human cell lines and
RT   tissues.";
RL   Genome Res. 23:555-567(2013).
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//
RX   PubMed=26342562; DOI=10.1016/j.scr.2015.08.008;
RA   Ross R.A., Walton J.D., Han D., Guo H.-F., Cheung N.-K.V.;
RT   "A distinct gene expression signature characterizes human
RT   neuroblastoma cancer stem cells.";
RL   Stem Cell Res. 15:419-426(2015).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//
RX   PubMed=33525507; DOI=10.3390/biom11020177;
RA   Mercatelli D., Balboni N., Palma A., Aleo E., Sanna P.P., Perini G.,
RA   Giorgi F.M.;
RT   "Single-cell gene network analysis and transcriptional landscape of
RT   MYCN-amplified neuroblastoma cell lines.";
RL   Biomolecules 11:177.1-177.18(2021).
//